According to the Northeast Pharmaceutical announcement, the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” with the approval and issuance of mabalosavir by the State Drug Administration, which is valid until July 19, 2031. Mabalosavir can exert anti-influenza virus activity, and its formulation is suitable for people. The approval for the marketing of this API is beneficial to enriching the company's product pipeline and enhancing competitiveness. However, due to factors such as GMP inspection progress, policies, markets, and patents, there is uncertainty about the production and sales time and situation, reminding investors to be aware of the risks.

According to the Northeast Pharmaceutical announcement, the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” with the approval and issuance of mabalosavir by the State Drug Administration, which is valid until July 19, 2031. Mabalosavir can exert anti-influenza virus activity, and its formulation is suitable for people. The approval for the marketing of this API is beneficial to enriching the company's product pipeline and enhancing competitiveness. However, due to factors such as GMP inspection progress, policies, markets, and patents, there is uncertainty about the production and sales time and situation, reminding investors to be aware of the risks.